ReviewMikrochimica acta2026
Acoustofluidic enrichment of small extracellular vesicles: physical principles, microfluidic implementations, and prospects for Parkinson's disease liquid biopsy.
Review in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Reliable blood-based small extracellular vesicle (sEV) analysis for Parkinson's disease (PD) is constrained by co-isolation of lipoproteins and proteins from plasma. This review examines acoustofluidics as a sample-preprocessing and integration-enabling strategy for PD liquid biopsy. We first summarize the analytical value and limitations of sEV-associated α-synuclein, microRNA panels, and multi-omics cargo, and then compare conventional and microfluidic enrichment methods with particular attention to lipoprotein co-isolation, recovery, fraction purity, throughput, and compatibility with downstream assays. We further analyze the physical basis of acoustofluidic separation, including particle volume, density, compressibility, and acoustic contrast factor, and assess its potential integration with on-chip lysis, nucleic acid amplification, protein assays, and signal readout. Current evidence suggests that acoustofluidics can provide label-free, noncontact enrichment of sEV-containing fractions while offering a physical separation dimension complementary to size and buoyant density. However, it achieves reduced lipoprotein co-isolation rather than complete removal, yielding sEV-enriched fractions rather than highly pure isolates. Clinical translation will therefore require standardized pre-analytical workflows, explicit reporting of sEV recovery and lipoprotein depletion, demonstration that improved fraction quality enhances biomarker measurement, and prospective multicenter validation. Acoustofluidics should thus be viewed as a promising front-end technology for improving the analytical reliability and integration of PD sEV liquid biopsy rather than as an independent diagnostic method. The critical question remains whether improved sEV enrichment can ultimately translate into more reliable and clinically useful PD biomarker measurements. We use sEV terminology without assuming endosomal origin.
Indexed as
Identifiers
42918940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.